Silexion Therapeutics* stands at the cutting edge of cancer’s final frontier – the notorious KRAS mutation that drives some of medicine’s deadliest tumors. Their groundbreaking SIL-204 therapy isn’t just showing…
Posts published in “Wall Street Wire”
Actelis Networks (NASDAQ: ASNS)* demonstrated solid progress in Q1 2025, maintaining stable quarterly revenue while significantly improving gross margins to 35% (up from 30% in Q1 2024) and reducing net…
NeuroSense Therapeutics (NASDAQ: NRSN)* announces today it has successfully scaled-up PrimeC production to commercial levels, removing the final technical barrier before potential Canadian market entry worth $100-150M The Bottom Line…
Inspira Technologies (NASDAQ: IINN)* just announced something that investors may want to pay close attention to. The Company announced that Israel’s largest healthcare provider has approved its revolutionary life-support system…
Palatin Technologies (NYSE American: PTN)* announced today a significant $11.5 million financing deal expected to close May 8, with potential for an additional $11.5 million through milestone-related warrants. This financing,…
THE BOTTOM LINE: Inspira Technologies (NASDAQ: IINN)* is challenging the $19 billion mechanical ventilation industry with a revolutionary approach: delivering oxygen directly to the blood instead of forcing air into…
The Bottom Line: NeuroSense (NASDAQ: NRSN)* is on the verge of potentially transforming ALS treatment with PrimeC, a novel drug combo showing remarkable 36% reduction in disease progression and 43%…
Silexion Therapeutics Corp. (NASDAQ: SLXN)* recently released its full-year 2024 financial results and business update, showcasing remarkable progress in its clinical and preclinical programs targeting KRAS-driven cancers. Following these developments,…
Actelis Networks (NASDAQ: ASNS)*, a leader in cyber-hardened networking solutions, continues to strengthen its position in the critical infrastructure sector with its recent announcement of a new order from one…
Palatin Technologies’ (NYSE: PTN)* Oral MC4R Agonist Gets FDA Orphan Drug Status; Phase 2 Results in Drug Targeting $44 Billion Obesity Market Expected Any Day According to the Company, alongside…